HON vs PFE: Which Is the Better Buy?
Side-by-side comparison of Honeywell International Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-05.
Honeywell International Inc. · Industrials
$213.17
-14.5% upside to fair value
Grade D
VS
Pfizer Inc. · Healthcare
$26.33
+28.6% upside to fair value
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+28.6%).
PFE trades at a lower forward P/E
(19.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
HON |
PFE |
| Current Price |
$213.17 |
$26.33 |
| Fair Value Estimate |
$182.35 |
$33.85 |
| Upside to Fair Value |
-14.5%
|
+28.6%
|
| Market Cap |
$135.1B |
$149.8B |
| Forward P/E |
33.0x
|
19.3x
|
| EV / EBITDA |
23.9x
|
12.9x
|
| Price / Sales |
3.7x
|
2.4x
|
| Price / FCF |
32.4x
|
16.5x
|
| Revenue Growth YoY |
-6.9%
|
-1.2%
|
| Gross Margin |
36.9%
|
70.3%
|
| Operating Margin |
14.9%
|
24.7%
|
| Return on Equity |
23.6%
|
8.7%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
3.09%
|
6.06%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
Honeywell International Inc. is a diversified industrial conglomerate operating across Aerospace Technologies, Building Automation, Process Automation and Technology, and Safety and Productivity Solutions. The company benefits from a strong leadership team with deep internal experience and a history of strategic acquisitions that have expanded its portfolio into high-growth areas such as aerospac…
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating ma…
Accumulation Zones
| Metric |
HON |
PFE |
| Zone Low |
$136.76 |
$25.39 |
| Zone High |
$155.00 |
$28.77 |
| In Buy Zone? |
No
|
Yes
|